News Articles and Interviews
Sustainable Downstream Processing of Vaccines: The DiViNe Consortium (article published in EPM Magazine)
Priyabrata Pattnaik, director, Worldwide Vaccine Initiative, Merck talks about the need for downstream processing within vaccine production.
Read article
Billerica, Massachusetts: 27 September 2016
MilliporeSigma's AFS Water Systems Reduce Water Consumption (article published in R&D Magazine)
R&D Magazine features an R&D 100 Flashback, chosen from our R&D 100 archive of winners. This flashback is MilliporeSigma's AFS Water Systems, which won in 2015.
Read article
Billerica, Massachusetts: 18 November 2015
The Making Of MilliporeSigma (article published in Chemical and Engineering News)
On Nov. 18, Merck KGaA, Darmstadt, Germany, closed on the biggest acquisition in its 347-year history: The $17.0 billion purchase of the research-chemical supply house Sigma-Aldrich.
Read article
Billerica, Massachusetts: 29 September 2015
Merck Millipore Accepts Silver Stevie® Award for AFS® E Water Purification Systems at the 2015 American Business Awards℠
Merck Millipore, the Life Science division of Merck KGaA, Darmstadt, Germany, accepted a Silver Stevie® Award for its AFS® E Water Purification Systems at a banquet held on Friday, September 11 in San Francisco. The award was conferred by The American Business Awards℠, the premier business awards program in the United States.
Read article
China: 15 April 2015
Both pharmaceutical companies and their suppliers share an optimistic view on the Chinese biopharmaceutical market
As China strengthens its legal system and pharmaceutical companies demand increasingly advanced technologies, Merck Millipore, a technology-based company that provides products and services for biopharmaceutical companies, sees big opportunities for expansion in the Chinese market.
Read article in English | Go to Chinese publication
China: 13 April 2015
How do new biotechnologies promote the development of the pharmaceutical industry?
Interview with Dr. Udit Batra, CEO and President of Merck Millipore
In recent years, emerging biotechnologies covering areas as diverse as gene editing, next-generation genetic sequencing, and disposable biological products, have not only driven the rapid development of preclinical medicine, they have also created huge business opportunities for pharmaceutical companies, transforming the entire industry landscape.
Read article in English | Go to Chinese publication
China: 08 April 2015
Merck Millipore tells media in Shanghai it seeks to improve its position in the Chinese market
Recently, Dr. Udit Batra, CEO and President of Merck Millipore, and other executives from the company, attended Merck Millipore's media briefing in Shanghai. Dr. Udit Batra shared his views on the company's Chinese market development strategy, the recent acquisition of Sigma-Aldrich, and other issues with reporters.
Read article in English | Go to Chinese publication
China: 08 April 2015
Further Expansion in the Chinese Market
Interview with Dr. Udit Batra, CEO and President of Merck Millipore
On March 31, 2015, Dr. Udit Batra, CEO and President, Merck Millipore was interviewed by three reporters including Process Industry, in Shanghai. Dr. Udit Batra introduced Merck Millipore's business profile and future plans, emphasizing that Merck Millipore will focus on growth in emerging markets, particularly China. In the interview, Dr. Udit Batra also shared details of Merck Millipore's philosophy and recent trends.
Read article in English | Go to Chinese publication
China: 08 April 2015
GSK takes over Novartis' vaccines business amid large-scale integration of multinational pharmaceutical companies in China
As China's macroeconomic slow-down is gradually accepted as the "new normal" trend, foreign pharmaceutical companies are suffering ever more problems arising from rapid expansion and excessive infrastructure investment in recent years. These companies are trying to adapt to the new normal by taking necessary measures in terms of compliance, mergers and acquisitions, personnel restructuring, and so on.
Read article in English | Go to Chinese publication
China: 07 April 2015
Biotechnology Research & Development and the Chinese Market
Oriental Morning Post: How did you benefit from the pharmaceutical industry acquisitions in China last year?
Udit Batra: This has two benefits. One is to bring global products into China, and the second is to take Chinese products globally. Merck Millipore supports the processes both ways.
Read article in English | Go to Chinese publication
Mumbai, India: 8 January 2015
Sigma, AZ Electronic acquisitions to help Merck consolidate in India
German drugs and chemicals group Merck KGaA, which made a couple of acquisitions in speciality chemicals and pharma solutions space in 2014, expects these deals will help strengthen its position in its newly identified priority markets, including India. The group's life sciences solutions division Merck Millipore, which has been a leading provider of technology solutions and services to drug makers, will significantly benefit from the $17 billion global acquisition of Sigma-Aldrich Co. Llc to consolidate its position in India, where it has a large customer base. Sigma offers a whole range of products used in the development and manufacture of drug formulations and ingredients. Merck Millipore has a large customer base including almost all top pharmaceutical companies in India.
Watch the video